SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

T he effectiveness of modern drugs like Ozempic and Mounjaro has helped revolutionize weight loss and the health issues that ...